Suzano Eucafluff to Attend INDEX and CIDPEX in 2023
3.2.2023 16:58:00 EET | Business Wire | Press release
Suzano, the world’s largest hardwood pulp producer, will showcase its highly sustainable and innovative eucalyptus-based fluff pulp, Eucafluff®, at this year’s INDEX and CIDEPX conferences in Geneva and Nanjing, for the second consecutive year. These two conferences gather the pulp industry’s leading participants in nonwoven materials comprising decision-makers, managers, and technical personnel. Suzano will be presenting significant advancements in Eucafluff’s product application and performance.
INDEX is one of the world’s largest nonwovens exhibitions exploring the industry’s latest trends and innovations. The event takes place on 18-21 April 2023 in Geneva, Switzerland.
CIDPEX – The China International Disposable Paper Expo - is another important event for Suzano which stages the latest advancements across the tissue paper and disposable hygiene products sector. The event takes place on 12-16 May 2023 in Nanjing, China.
Eucafluff® is made from sustainably managed eucalyptus farms in São Paulo and is the result of nearly 15 years of R&D. Its absorbent panels, made with 100% Eucafluff®, provides a more flexible, more discreet product for consumers. Eucafluff® outperforms its competitors in terms of rewetting, net retention and comfort performance due to the morphology of Suzano’s eucalyptus hardwood, which is smaller, thinner, and highly compressible. The result of this performance provides significant affordability with an 18% reduction of packaging material and 13% reduction in storage and volume. Furthermore, Eucafluff® provides a far more sustainable solution with a smaller carbon footprint and a lower impact on land use, using far less wood to produce the same amount of fluff.
Eucafluff has grown dramatically in recent years, increasing its application and sales across a range of fluff segments. Suzano’s Eucafluff® will continue to pursue an ambitious growth strategy, particularly as it accelerates an ongoing roll-out to the baby diaper segment while also targeting the rapidly expanding adult diaper market.
About Suzano
Suzano is the world’s largest producer of hardwood pulp and the global leader in the innovation and production of renewable, bio-based materials for consumer and industrial use. Our responsibly-grown materials provide over 2 billion people in more than 100 countries with plastic free products including writing paper, tissue, paper cups and straws, paperboard packaging, toilet paper, textiles, diapers and more. We are pioneers in sustainable mass scale industrial production, and our ethos of innovability – the pursuit of sustainable solutions through innovation – is at the core of all our work, from the field to our factories and labs, all the way to the end user. Suzano’s history spans 100 years and is listed on the B3 stock exchange in Brazil (SUZB3) and the NYSE (SUZ) in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005241/en/
Contact information
Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom